Basit öğe kaydını göster

Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever

dc.contributor.authorKorkmaz, Merve
dc.contributor.authorSeyahi, Nurhan
dc.contributor.authorTrabulus, Sinan
dc.contributor.authorKaya, Eda
dc.date.accessioned2021-03-03T11:10:58Z
dc.date.available2021-03-03T11:10:58Z
dc.date.issued2018
dc.identifier.citationTrabulus S., Korkmaz M., Kaya E., Seyahi N., "Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever", CLINICAL TRANSPLANTATION, cilt.32, sa.8, 2018
dc.identifier.issn0902-0063
dc.identifier.otherav_26745c2c-0cfb-400c-b187-cb7a3eda51f1
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/30736
dc.identifier.urihttps://doi.org/10.1111/ctr.13345
dc.description.abstractBackground: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti-interleukin-1 drugs emerge as a therapeutic option for colchicine-resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.
dc.language.isoeng
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectCerrahi Tıp Bilimleri
dc.subjectTRANSPLANTASYON
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectCERRAHİ
dc.titleCanakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever
dc.typeMakale
dc.relation.journalCLINICAL TRANSPLANTATION
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume32
dc.identifier.issue8
dc.contributor.firstauthorID255057


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster